Bone regeneration in compromised wounds

Patent metadata

Field	Value
Publication number	US-12440604-B2
Application number	US-201917055046-A
Country	US
Kind code	B2
Filing date	Jun 13, 2019
Priority date	Jun 13, 2018
Publication date	Oct 14, 2025
Grant date	Oct 14, 2025

Abstract

Biomaterials disclosed herein can comprise a hydrogel comprising PEG, gelatin, and a glycosaminoglycan with sulfated moiety; and chondrogenic, osteogenic, and immunomodulatory cytokines; wherein the biomaterial is capable of potentiating bone regeneration in a compromised wound while reducing inflammatory response. The glycosaminoglycan with sulfated moiety can comprise heparin, heparan sulfate, keratin sulfate, chondroitin sulfate, dermatan sulfate, and/or similar materials. The biomaterial can further comprise mesenchymal stem cells (MSCs), a crosslinking initiator, microparticles and nanoparticles, and or other materials. The biomaterial can be injectable into a wound, or the biomaterial can be loaded in, or further comprise a porous scaffold providing mechanical support for other components of the biomaterial, such that it can be implanted into a wound.

First claim

The invention claimed is:

1. A biomaterial comprising:
a hydrogel comprising the crosslinked polymers PEG, gelatin, and a glycosaminoglycan with sulfated moiety, wherein a ratio of the glycosaminoglycan with sulfated moiety to the PEG by mass is 1/1 or greater; and
chondrogenic, osteogenic, and immunomodulatory cytokines, wherein the cytokines comprise TGF-β1;
wherein the biomaterial is acellular, the biomaterial comprises about 1 mg/ml of the TGF-β1, and the biomaterial is capable of potentiating bone regeneration in a compromised wound while reducing inflammatory response in a large animal.

2. The biomaterial of claim 1 , wherein a ratio of the gelatin to the PEG by mass is 1/1 or greater.

3. The biomaterial of claim 1 , wherein the hydrogel comprises from 7.5% to 8.5% mass of PEG, gelatin, and a glycosaminoglycan with sulfated moiety to the volume of hydrogel.

4. The biomaterial of claim 1 , wherein the glycosaminoglycan with sulfated moiety comprises heparin.

5. The biomaterial of claim 1 , wherein the glycosaminoglycan with sulfated moiety comprises chondroitin sulfate.

6. The biomaterial of claim 1 , further comprising a crosslinking initiator.

7. The biomaterial of claim 1 , further comprising a porous scaffold providing mechanical support for other components of the biomaterial.

8. A method comprising injecting or implanting the biomaterial of claim 1 into a compromised wound.

9. The method of claim 8 , wherein the injected or implanted biomaterial suppresses inflammatory response and potentiates bone regeneration at the compromised wound.

10. The biomaterial of claim 1 , wherein the large animal comprises a human or a swine.

11. The biomaterial of claim 1 , wherein:
the glycosaminoglycan with sulfated moiety comprises heparin; and
the hydrogel comprises the PEG, the gelatin, and the heparin in about a 3:4:3 proportion by mass.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education

Inventors

• Taboas Juan M
• Almarza Alejandro Jose
• Chen Jingming

Classifications

• A61M5/19

  having more than one chamber {, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly (surgical glue applicators A61B17/00491)} · CPC title

• A61L2430/02

  for reconstruction of bones; weight-bearing implants · CPC title

• A61L2400/06

  Flowable or injectable implant compositions · CPC title

• A61L2300/426

  Immunomodulating agents, i.e. cytokines, interleukins, interferons · CPC title

• A61L2300/414

  Growth factors · CPC title